# Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients

Source: https://onco.cc/trials/nct06514508/  
OnCo record `nct06514508` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Motixafortide, Filgrastim in multiple myeloma, run by Guangzhou Gloria Biosciences Co., Ltd., now recruiting.

## Summary

Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients is a phase 3 interventional study registered as NCT06514508 by Guangzhou Gloria Biosciences Co., Ltd., with 60 participants planned, started 2025-12-01 and due to reach its primary completion in 2026-09-11. Interventions recorded: Motixafortide+G-CSF, Placebo+G-CSF. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06514508
- Phase: 3
- Setting: A Phase Ⅲ, Randomized, Double-Blinded Study Evaluating the Safety and Efficacy of Combination Treatment of Motixafortide and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma
- Sponsor: Guangzhou Gloria Biosciences Co., Ltd.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06514508: https://clinicaltrials.gov/study/NCT06514508

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Filgrastim (G-CSF)](https://onco.cc/drugs/filgrastim/), [Motixafortide](https://onco.cc/drugs/motixafortide/)

---
JSON: https://onco.cc/api/v1/entities/nct06514508.json